Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COCH Envoy Medical	$1.51 +1.7%	$1.50	$1.21 ▼ $3.99	$32.08M	2.29	80,207 shs	4,062 shs
LUNG Pulmonx	$2.63 +1.5%	$3.49	$2.50 ▼ $9.37	$105.88M	0.52	305,581 shs	28,365 shs
MGRM Monogram Orthopaedics	$2.87 -0.7%	$2.71	$1.92 ▼ $4.20	$102.43M	0.41	364,540 shs	22,711 shs
OBIO Orchestra BioMed	$3.05 +2.2%	$2.92	$2.37 ▼ $8.87	$116.65M	0.64	268,323 shs	49,625 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COCH Envoy Medical	+2.07%	+5.71%	-5.13%	+8.82%	-31.16%
LUNG Pulmonx	-1.52%	-5.82%	-16.18%	-62.02%	-57.82%
MGRM Monogram Orthopaedics	+0.70%	-1.37%	+9.89%	+3.58%	+43.07%
OBIO Orchestra BioMed	-3.56%	-0.33%	+5.67%	-32.27%	-56.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COCH Envoy Medical	2.4361 of 5 stars	3.5	2.0	2.2	3.3	0.0
LUNG Pulmonx	3.7 of 5 stars	3.3	5.0	3.3	3.3	0.6
MGRM Monogram Orthopaedics	2.898 of 5 stars	3.8	2.0	3.3	1.7	0.6
OBIO Orchestra BioMed	2.0507 of 5 stars	3.6	3.0	2.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COCH Envoy Medical	3.00	Buy	$9.25	514.62% Upside
LUNG Pulmonx	2.63	Moderate Buy	$11.53	338.21% Upside
MGRM Monogram Orthopaedics	3.50	Strong Buy	$5.40	88.15% Upside
OBIO Orchestra BioMed	3.20	Buy	$14.20	366.34% Upside

Current Analyst Ratings Breakdown

Latest COCH, OBIO, LUNG, and MGRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	COCH Envoy Medical	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.25 ➝ $9.50
5/22/2025	LUNG Pulmonx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.50 ➝ $4.15
5/13/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/5/2025	OBIO Orchestra BioMed	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $12.00
5/1/2025	LUNG Pulmonx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/1/2025	LUNG Pulmonx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$10.00 ➝ $9.00
5/1/2025	LUNG Pulmonx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/23/2025	OBIO Orchestra BioMed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/22/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/21/2025	COCH Envoy Medical	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $9.25
4/4/2025	OBIO Orchestra BioMed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COCH Envoy Medical	$220K	145.92	N/A	N/A	($0.88) per share	-1.71
LUNG Pulmonx	$83.79M	1.26	N/A	N/A	$2.17 per share	1.21
MGRM Monogram Orthopaedics	$370K	276.84	N/A	N/A	$0.42 per share	6.83
OBIO Orchestra BioMed	$2.64M	44.19	N/A	N/A	$0.87 per share	3.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COCH Envoy Medical	-$20.80M	-$1.38	N/A	N/A	N/A	-10,656.13%	N/A	-237.44%	8/11/2025 (Estimated)
LUNG Pulmonx	-$56.39M	-$1.44	N/A	N/A	N/A	-65.27%	-63.69%	-34.94%	7/30/2025 (Estimated)
MGRM Monogram Orthopaedics	-$16.33M	-$0.45	N/A	N/A	N/A	N/A	-115.71%	-92.75%	8/13/2025 (Estimated)
OBIO Orchestra BioMed	-$61.02M	-$1.78	N/A	N/A	N/A	-2,297.85%	-189.26%	-93.76%	N/A

Latest COCH, OBIO, LUNG, and MGRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MGRM Monogram Orthopaedics	-$0.12	-$0.10	+$0.02	-$0.10	N/A	N/A
5/12/2025	Q1 2025	OBIO Orchestra BioMed	-$0.46	-$0.49	-$0.03	-$0.49	$0.39 million	$0.87 million
5/7/2025	Q1 2025	LUNG Pulmonx	-$0.37	-$0.36	+$0.01	-$0.36	$22.03 million	$22.54 million
3/31/2025	Q4 2024	OBIO Orchestra BioMed	-$0.43	-$0.43	N/A	-$0.43	$0.79 million	$0.25 million
3/28/2025	Q4 2024	COCH Envoy Medical	-$0.33	-$0.45	-$0.12	-$0.45	$0.07 million	$0.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COCH Envoy Medical	N/A	N/A	N/A	N/A	N/A
LUNG Pulmonx	N/A	N/A	N/A	N/A	N/A
MGRM Monogram Orthopaedics	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COCH Envoy Medical	N/A	1.09	0.88
LUNG Pulmonx	0.38	4.97	4.29
MGRM Monogram Orthopaedics	N/A	7.00	7.00
OBIO Orchestra BioMed	0.85	3.35	3.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COCH Envoy Medical	8.59%
LUNG Pulmonx	91.04%
MGRM Monogram Orthopaedics	0.45%
OBIO Orchestra BioMed	53.55%

Insider Ownership

Company	Insider Ownership
COCH Envoy Medical	58.90%
LUNG Pulmonx	6.80%
MGRM Monogram Orthopaedics	28.10%
OBIO Orchestra BioMed	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COCH Envoy Medical	34	21.33 million	8.77 million	Not Optionable
LUNG Pulmonx	250	40.26 million	37.52 million	Optionable
MGRM Monogram Orthopaedics	28	35.69 million	25.66 million	Not Optionable
OBIO Orchestra BioMed	4	38.31 million	35.21 million	Not Optionable

COCH, OBIO, LUNG, and MGRM Headlines

Recent News About These Companies

Orchestra BioMed Confirms Director Elections and Auditor

June 24 at 4:39 PM | tipranks.com

Orchestra BioMed Highlights Potential of AVIM Therapy for Managing Hypertension in High-Risk Patients at CSI 2025 Meeting

June 20, 2025 | nasdaq.com

Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting

June 18, 2025 | msn.com

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

June 18, 2025 | globenewswire.com

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships

May 28, 2025 | seekingalpha.com

Orchestra BioMed Holdings - Breakthrough Device Designation Gives Speculative Optimism

May 14, 2025 | seekingalpha.com

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates

May 12, 2025 | zacks.com

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

May 12, 2025 | globenewswire.com

Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation

May 11, 2025 | msn.com

Orchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global Patents

May 9, 2025 | nasdaq.com

Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 19.92%

May 9, 2025 | aaii.comA

Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

May 8, 2025 | finance.yahoo.com

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

May 7, 2025 | globenewswire.com

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

May 5, 2025 | zacks.com

Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment

May 1, 2025 | msn.com

Orchestra BioMed to Present at Jefferies Global Healthcare Conference

May 1, 2025 | msn.com

Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 7.51%

May 1, 2025 | aaii.comA

FDA approves head-to-head trial of Orchestra BioMed’s balloon

April 30, 2025 | investing.com

Orchestra BioMed wins FDA IDE for sirolimus-angioballoon

April 29, 2025 | massdevice.com

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

April 29, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Southwest Airlines: Short Interest Plunges—Should You Buy?
By Gabriel Osorio-Mazilli | June 17, 2025
View Southwest Airlines: Short Interest Plunges—Should You Buy?

COCH, OBIO, LUNG, and MGRM Company Descriptions

Envoy Medical NASDAQ:COCH

$1.50 +0.03 (+1.69%)

As of 11:57 AM Eastern

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

Pulmonx NASDAQ:LUNG

$2.63 +0.04 (+1.54%)

As of 12:00 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Monogram Orthopaedics NASDAQ:MGRM

$2.87 -0.02 (-0.69%)

As of 11:56 AM Eastern

Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas.

Orchestra BioMed NASDAQ:OBIO

$3.04 +0.07 (+2.18%)

As of 11:59 AM Eastern

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time